Molecular properties and therapeutic targeting of the ebv-encoded receptor bilf1
Research output: Contribution to journal › Review › Research › peer-review
Standard
Molecular properties and therapeutic targeting of the ebv-encoded receptor bilf1. / Knerr, Julius Maximilian; Kledal, Thomas Nitschke; Rosenkilde, Mette Marie.
In: Cancers, Vol. 13, No. 16, 4079, 2021.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Molecular properties and therapeutic targeting of the ebv-encoded receptor bilf1
AU - Knerr, Julius Maximilian
AU - Kledal, Thomas Nitschke
AU - Rosenkilde, Mette Marie
N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - The γ-herpesvirus Epstein–Barr Virus (EBV) establishes lifelong infections in approximately 90% of adults worldwide. Up to 1,000,000 people yearly are estimated to suffer from health conditions attributed to the infection with this virus, such as nasopharyngeal and gastric carcinomas as well as several forms of B, T and NK cell lymphoma. To date, no EBV-specific therapeutic option has reached the market, greatly reducing the survival prognoses of affected patients. Similar to other herpesviruses, EBV encodes for a G protein–coupled receptor (GPCR), BILF1, affecting a multitude of cellular signaling pathways. BILF1 has been identified to promote immune evasion and tumorigenesis, effectively ensuring a life-long persistence of EBV in, and driving detrimental health conditions to its host. This review summarizes the epidemiology of EBV-associated malignancies, their current standard-of-care, EBV-specific therapeutics in development, GPCRs and their druggability, and most importantly consolidates the findings of over 15 years of research on BILF1 in the context of EBV-specific drug development. Taken together, BILF1 constitutes a promising target for the development of novel EBV-specific therapeutics.
AB - The γ-herpesvirus Epstein–Barr Virus (EBV) establishes lifelong infections in approximately 90% of adults worldwide. Up to 1,000,000 people yearly are estimated to suffer from health conditions attributed to the infection with this virus, such as nasopharyngeal and gastric carcinomas as well as several forms of B, T and NK cell lymphoma. To date, no EBV-specific therapeutic option has reached the market, greatly reducing the survival prognoses of affected patients. Similar to other herpesviruses, EBV encodes for a G protein–coupled receptor (GPCR), BILF1, affecting a multitude of cellular signaling pathways. BILF1 has been identified to promote immune evasion and tumorigenesis, effectively ensuring a life-long persistence of EBV in, and driving detrimental health conditions to its host. This review summarizes the epidemiology of EBV-associated malignancies, their current standard-of-care, EBV-specific therapeutics in development, GPCRs and their druggability, and most importantly consolidates the findings of over 15 years of research on BILF1 in the context of EBV-specific drug development. Taken together, BILF1 constitutes a promising target for the development of novel EBV-specific therapeutics.
KW - Antiviral treatment
KW - BILF1
KW - Cancer
KW - Constitutive activity
KW - Epstein–Barr virus
KW - G protein–coupled receptor
KW - Oncogenic virus
UR - http://www.scopus.com/inward/record.url?scp=85112348867&partnerID=8YFLogxK
U2 - 10.3390/cancers13164079
DO - 10.3390/cancers13164079
M3 - Review
C2 - 34439235
AN - SCOPUS:85112348867
VL - 13
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 16
M1 - 4079
ER -
ID: 281109507